secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001689548-23-000084
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis reports Q1 net loss $37.5M; PRAX-628 Phase 1 positive, cash runway into Q2 2024
--------------------------------------------------------------------------------

- Q1 net loss $37.5M ($0.65 per share); cash & investments $85.8M as of March 31, 2023, funding operations into Q2 2024.
- PRAX-628 Phase 1 well-tolerated; PK supports once-daily dosing; concentrations >15-fold MES EC50, indicating potential best-in-class efficacy for focal epilepsy.
- Ulixacaltamide End-of-Phase 2 FDA meeting scheduled June 2023; Phase 3 program in essential tremor planned for H2 2023.
- PRAX-562 EMBOLD study topline results expected Q4 2023; PRAX-222 EMBRAVE topline results expected H2 2023.
- R&D expenses decreased to $25.5M from $52.7M YoY; G&A expenses decreased to $13.3M from $16.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954823000084/0001689548-23-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954823000084/prax-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001689548-23-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer